A review of kallikrein inhibitor lanadelumab in hereditary angioedema
A review of kallikrein inhibitor lanadelumab in hereditary angioedema
About this item
Full title
Author / Creator
Publisher
London: Future Medicine Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Future Medicine Ltd
Subjects
More information
Scope and Contents
Contents
Hereditary angioedema with C1 esterase inhibitor deficiency is a rare disorder characterized by unpredictable swelling of the face, larynx and gastrointestinal tract. Kallikreins are serine proteases that cleave kininogens to produce bradykinin leading to inflammation. A new prophylactic drug is lanadelumab (DX-2930, SHP-643), a recombinant, fully...
Alternative Titles
Full title
A review of kallikrein inhibitor lanadelumab in hereditary angioedema
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2276754145
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2276754145
Other Identifiers
ISSN
1750-743X
E-ISSN
1750-7448
DOI
10.2217/imt-2018-0197
